Ecallantide (Kalbitor)

Kalbitor (ecallantide) is covered only for acute HAE attacks due to C1‑INH deficiency (type I or II) and is not supported for HAE with normal C1‑INH or other non‑FDA indications. Coverage requires baseline labs showing functional C1‑INH <50% and low serum C4, prescription by or in consultation with an HAE specialist, dosing 30 mg SC (no more than twice daily), 12‑month approvals, and reauthorization only after prior Kalbitor use with documented favorable clinical response.

"Kalbitor is indicated for the treatment of acute Hereditary Angioedema (HAE) attacks."

Sign up to see full coverage criteria, indications, and limitations.